Clinical Trials
24
Active:0
Completed:18
Trial Phases
3 Phases
Phase 1:12
Phase 2:9
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 1
12 (52.2%)Phase 2
9 (39.1%)Phase 3
2 (8.7%)A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Lymphoma Including ENKL
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT06761677
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
🇯🇵Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Japan
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
Phase 2
Terminated
- Conditions
- Kidney TransplantationBK Virus InfectionNephropathy
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT05511779
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Phase 2
Recruiting
- Conditions
- Adenovirus InfectionsCytomegalovirus Infection
- Interventions
- Drug: BCV
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT04706923
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04542252
- Locations
- 🇯🇵
Research Site, Hachioji-shi, Tokyo, Japan
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL
Completed
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT04354402
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found